Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors
- PMID: 27210433
- DOI: 10.1016/j.bmcl.2016.05.014
Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors
Abstract
A series of novel 4,5,6-trisubstituted pyrimidines were designed as potent covalent Bruton's tyrosine kinase (BTK) inhibitors based on the structure of ibrutinib by using a ring-opening strategy. Among these derivatives, compound I1 exhibited the most potent inhibitory activity with an IC50 value of 0.07μM. The preliminary structure-activity relationship was discussed and the primary amino group at the C-4 position of pyrimidine was crucial for maintaining BTK activity. Furthermore, molecular dynamics simulations and binding free energy calculations were performed for three inhibitor-BTK complexes to determine the probable binding model, which provided a comprehensive guide for further structural modification and optimization.
Keywords: BTK; Covalent kinase inhibitor; Molecular dynamics simulation; Pyrimidine; Structure–activity relationship.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.Acta Pharmacol Sin. 2020 Mar;41(3):415-422. doi: 10.1038/s41401-019-0250-8. Epub 2019 Jul 17. Acta Pharmacol Sin. 2020. PMID: 31316181 Free PMC article.
-
A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.Sci Rep. 2015 Nov 4;5:16136. doi: 10.1038/srep16136. Sci Rep. 2015. PMID: 26531233 Free PMC article.
-
Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.Bioorg Med Chem. 2015 Feb 15;23(4):891-901. doi: 10.1016/j.bmc.2014.10.043. Epub 2014 Nov 6. Bioorg Med Chem. 2015. PMID: 25596757
-
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.Future Med Chem. 2018 Feb;10(3):343-356. doi: 10.4155/fmc-2017-0145. Epub 2018 Jan 19. Future Med Chem. 2018. PMID: 29347836 Review.
-
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342. Anticancer Agents Med Chem. 2017. PMID: 27697038 Review.
Cited by
-
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.Onco Targets Ther. 2017 Mar 29;10:1909-1914. doi: 10.2147/OTT.S98689. eCollection 2017. Onco Targets Ther. 2017. PMID: 28408842 Free PMC article. Review.
-
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841. Curr Pharm Des. 2022. PMID: 36345244
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous